Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM-001 CRISPR-Cas9 Edited Autologous CD34+ HSPC in Transfusion-Dependent Beta Thalassemia
TCTR20250828001Phase 1Not yet recruiting
- Sponsor
- Investigator Initiated Trial
- Start
- Jan 2026
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of γ-globin reactivated autologous hematopoietic stem cells in beta thalassemia, sponsored by Investigator Initiated Trial. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
γ-globin reactivated autologous hematopoietic stem cells
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on TCTR20250828001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250828001.